Drug Trial Radar · NCT03333057
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
336
Actual
Start
Jan 3, 2018
Primary completion
May 18, 2018
Study completion Jul 27, 2018
Sponsor
- Lead sponsor
- Novaliq GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
Conditions
- Dry Eye Disease (DED)
Interventions
NOV03Drug
Perfluorohexyloctane
PlaceboDrug
Saline solution (0.9% sodium chloride solution)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal Fluorescein Staining (CFS) Total (National Eye Institute (NEI) Grading)Time frame: baseline and 2 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Investigational site
Artesia, California
Investigational Site
Newport Beach, California
Investigational Site
Newport Beach, California
Investigational Site
Santa Ana, California
Investigational Site
Torrance, California
Investigational site
Jacksonville, Florida
Investigational Site
Lake Villa, Illinois
Investigational Site
Kansas City, Missouri
Investigational Site
Pennington, New Jersey
Investigational Site
Nashville, Tennessee
Investigational Site
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.